New indication for Plavix wins priority review status

The FDA has given Sanofi-Aventis' Plavix priority review status for a new indication to treat arteries blocked long enough to trigger muscle damage. Already approved to prevent blood clots, Sanofi-Aventis says that one third of all heart attacks include blocked arteries. A priority review should shave four months off the time the FDA takes to decide on a drug, helping to speed it to the market.

- read this report from AFX for more